/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | LABTLakewood-Amedex Biot |
|---|---|
| Last close | $0.39close 2026-11-06 |
| Change % | -28.54%close 2026-11-06 |
| Market cap | $915410.4744close 2026-11-06 |
| P/E | loss, no P/E |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $-3847637⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingS-1 · 0001213900-26-101512 · filed 2026-09-18 Open the filing on EDGAR →Open the XBRL payload →CiteLakewood-Amedex Biotherapeutics Inc. (LABT), us-gaap:NetIncomeLoss: -3,847,637 USD, fiscal year ended 2025-12-31. Form S-1, accession 0001213900-26-101512, filed 2026-09-18. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0002079272/us-gaap/NetIncomeLoss.json |
| Net margin | not filed |
| EPS (diluted) | $-8.40⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 FilingS-1 · 0001213900-26-101512 · filed 2026-09-18 Open the filing on EDGAR →Open the XBRL payload →CiteLakewood-Amedex Biotherapeutics Inc. (LABT), us-gaap:EarningsPerShareDiluted: -8.40 USD per share, fiscal year ended 2025-12-31. Form S-1, accession 0001213900-26-101512, filed 2026-09-18. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0002079272/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | — |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.